Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993146 · ClinicalTrials.gov registry record · Phase 1
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 14
- Study locations
NCT02993146 is a Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT02993146, a Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- RADIATION Whole-Brain Radiotherapy
- DRUG Ropidoxuridine
Study Locations (14)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Wayne State University/Karmanos Cancer Institute - Detroit
- Weisberg Cancer Treatment Center - Farmington Hills
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- Ben Taub General Hospital - Houston
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2026-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993146
The ClinicalTrials.gov registry entry for NCT02993146 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02993146 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Michigan, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02993146 about?
NCT02993146 is a clinical study titled "Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases". This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cell...
What is the current status of trial NCT02993146?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-05-08. Estimated completion is 2026-10-03.
What conditions does trial NCT02993146 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm in the Brain.
What interventions are being tested in trial NCT02993146?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Whole-Brain Radiotherapy (RADIATION), Ropidoxuridine (DRUG).
Who is sponsoring clinical trial NCT02993146?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02993146 being conducted?
This trial has 14 study locations across California, Iowa, Maryland, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
RECRUITING · Phase 1
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.